|
|
|
Insider
Information: |
Enright Patrick G |
Relationship: |
10% Owner |
City: |
Burlingame |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
16 |
|
Direct
Shares |
3,308,185 |
|
Indirect Shares
|
27,432,603 |
|
|
Direct
Value |
$10,512,905 |
|
|
Indirect Value
|
$115,077,943 |
|
|
Total
Shares |
30,740,788 |
|
|
Total
Value |
$125,590,848 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
6
|
1
|
Stock
price went up :
|
5
|
1
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
5.0
|
1.0
|
Percentage
Gain/Loss : |
95.0%
|
101.2%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Molecular Templates, Inc. |
MTEM |
Director |
2006-04-20 |
496 |
2007-03-01 |
0 |
Premium* |
|
Sequenom Inc |
SQNM |
Director |
2006-12-07 |
771 |
2006-12-07 |
3,333,333 |
Premium* |
|
Corcept Therapeutics Inc |
CORT |
Director |
2017-03-16 |
272,281 |
2017-03-16 |
114,675 |
Premium* |
|
Jazz Pharmaceuticals Inc |
JAZZ |
Director |
2023-08-14 |
20,946 |
2022-08-08 |
2,000 |
Premium* |
|
Esperion Therapeutics, Inc. |
ESPR |
Director |
2013-07-01 |
0 |
2015-03-19 |
18,361 |
Premium* |
|
Collegium Pharmaceutical, Inc |
COLL |
10% Owner |
2015-05-12 |
0 |
2015-05-12 |
65,270 |
Premium* |
|
Aimmune Therapeutics, Inc. |
AIMT |
Director |
2020-10-13 |
0 |
2020-10-10 |
0 |
Premium* |
|
Aptinyx Inc. |
APTX |
Director |
2020-01-10 |
95,000 |
2020-01-10 |
3,356,746 |
Premium* |
|
Tricida, Inc. |
TCDA |
|
2018-07-02 |
0 |
2018-07-02 |
3,019,734 |
Premium* |
|
Venus Concept Inc |
VERO |
10% Owner |
|
0 |
2019-11-07 |
3,666,119 |
Premium* |
|
89bio, Inc. |
ETNB |
10% Owner |
2019-11-11 |
0 |
2020-11-16 |
891 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
10% Owner |
2020-01-29 |
0 |
2022-01-25 |
1,964,771 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
0 |
2022-04-19 |
4,174,379 |
Premium* |
|
Eargo, Inc. |
EAR |
10% Owner |
2021-04-14 |
2,918,691 |
2021-04-14 |
5,012 |
Premium* |
|
Vera Therapeutics, Inc. |
VERA |
Director, 10% Owner |
2021-05-18 |
0 |
2023-02-06 |
5,144,212 |
Premium* |
|
Lexeo Therapeutics, Inc. |
LXEO |
10% Owner |
2023-11-07 |
0 |
2023-11-07 |
2,567,100 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
169 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CORT |
Corcept Therapeutics Inc |
Director |
|
2016-11-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,000,000) |
121,153 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2016-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
204,210 |
204,210 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2017-02-23 |
4 |
S |
$8.65 |
$12,975,000 |
I/I |
(1,500,000) |
185,807 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2017-02-27 |
4 |
S |
$9.05 |
$9,050,000 |
I/I |
(1,000,000) |
166,157 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2017-03-13 |
4 |
S |
$11.13 |
$233,491 |
I/I |
(20,980) |
151,008 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2017-03-14 |
4 |
S |
$10.01 |
$3,002,670 |
I/I |
(300,000) |
145,113 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2017-03-15 |
4 |
S |
$10.24 |
$2,856,766 |
I/I |
(279,020) |
139,630 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2017-03-16 |
4 |
S |
$9.94 |
$2,683,237 |
I/I |
(269,955) |
114,675 |
0 |
- |
|
EAR |
Eargo, Inc. |
10% Owner |
|
2021-04-14 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,000,000) |
2,918,691 |
0 |
- |
|
EAR |
Eargo, Inc. |
10% Owner |
|
2021-04-14 |
4 |
A |
$0.00 |
$0 |
I/I |
5,012 |
5,012 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2013-07-01 |
4 |
B |
$14.00 |
$3,033,464 |
I/I |
216,676 |
38,011 |
2.25 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2013-07-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,717,720 |
33,753 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2014-10-07 |
4 |
S |
$30.04 |
$358,289 |
I/I |
(11,927) |
37,776 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2014-10-09 |
4 |
S |
$30.00 |
$28,290 |
I/I |
(943) |
37,757 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2014-11-17 |
4 |
S |
$32.01 |
$15,804,823 |
I/I |
(482,026) |
28,286 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2014-11-18 |
4 |
S |
$31.56 |
$161,346 |
I/I |
(5,104) |
28,186 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2015-03-19 |
4 |
S |
$110.01 |
$55,831,597 |
I/I |
(500,000) |
18,361 |
0 |
- |
|
ETNB |
89bio, Inc. |
10% Owner |
|
2019-11-11 |
4 |
B |
$16.00 |
$9,200,000 |
I/I |
575,000 |
575,000 |
1.5 |
- |
|
ETNB |
89bio, Inc. |
10% Owner |
|
2019-11-13 |
4 |
A |
$0.00 |
$0 |
I/I |
1,916,787 |
2,491,787 |
0 |
- |
|
ETNB |
89bio, Inc. |
10% Owner |
|
2020-07-10 |
4 |
B |
$27.50 |
$2,999,975 |
I/I |
109,090 |
2,600,877 |
1.5 |
% |
|
ETNB |
89bio, Inc. |
10% Owner |
|
2020-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
5,944 |
891 |
0 |
- |
|
ETNB |
89bio, Inc. |
10% Owner |
|
2020-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(850,000) |
1,750,877 |
0 |
- |
|
INZY |
Inozyme Pharma, Inc. |
10% Owner |
|
2020-07-28 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
2,819,379 |
1.5 |
- |
|
INZY |
Inozyme Pharma, Inc. |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
2,194,379 |
2,194,379 |
0 |
- |
|
INZY |
Inozyme Pharma, Inc. |
10% Owner |
|
2022-04-19 |
4 |
B |
$3.69 |
$4,999,950 |
I/I |
1,355,000 |
4,174,379 |
1.5 |
- |
|
169 Records found
|
|
Page 3 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|